FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.
作者信息
Thomson A W, Carroll P B, McCauley J, Woo J, Abu-Elmagd K, Starzl T E, Van Thiel D H
机构信息
Transplant Institute, University of Pittsburgh, PA 15213.
出版信息
Springer Semin Immunopathol. 1993;14(4):323-44. doi: 10.1007/BF00192307.
Abstract
摘要
相似文献
1
FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.FK506：一种用于治疗自身免疫性疾病的新型免疫抑制剂。匹兹堡大学的理论依据及初步临床经验
Springer Semin Immunopathol. 1993;14(4):323-44. doi: 10.1007/BF00192307.
2
[Clinical experience with FK 506].
Presse Med. 1991 Nov 27;20(40):1967-73.
3
Cyclosporine therapy for autoimmune disease.用于自身免疫性疾病的环孢素疗法。
N Engl J Med. 1992 Jun 18;326(25):1693-5. doi: 10.1056/NEJM199206183262509.
4
FK-506--a novel immunosuppressant.
Ann N Y Acad Sci. 1993 Jun 23;685:22-36. doi: 10.1111/j.1749-6632.1993.tb35847.x.
5
Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial.19例参与开放标签药物安全性试验的慢性进行性多发性硬化症患者中，FK 506（他克莫司）对表达CD25和CD45RA抗原的循环CD4 + T细胞的影响。
Autoimmunity. 1994;19(2):89-98. doi: 10.3109/08916939409009536.
6
Cyclosporine in autoimmune diseases.环孢素在自身免疫性疾病中的应用。
Transplant Proc. 1989 Jun;21(3 Suppl 1):97-113.
7
Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.
N Engl J Med. 1992 Jun 18;326(25):1654-60. doi: 10.1056/NEJM199206183262502.
8
Calcineurin inhibitors: 40 years later, can't live without ..钙调磷酸酶抑制剂：40 年后，不可或缺的药物..
J Immunol. 2013 Dec 15;191(12):5785-91. doi: 10.4049/jimmunol.1390055.
9
Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506.环孢素肾毒性：病理生理学及与FK-506的比较。
Curr Opin Nephrol Hypertens. 1998 Sep;7(5):539-45. doi: 10.1097/00041552-199809000-00009.
10
Therapeutic anti-psoriatic effects of myeloid-derived suppressor cells in combination with systemic tacrolimus (FK-506) in an imiquimod-induced mouse model of psoriasis.咪喹莫特诱导的银屑病小鼠模型中髓源抑制细胞与全身他克莫司（FK-506）联合的抗银屑病治疗作用。
Int Immunopharmacol. 2020 Sep;86:106553. doi: 10.1016/j.intimp.2020.106553. Epub 2020 Jun 17.
引用本文的文献
1
Cell detoxification of secondary metabolites by P4-ATPase-mediated vesicle transport.P4-ATPase 介导体泡运输实现次生代谢物的细胞解毒。
Elife. 2023 Jul 4;12:e79179. doi: 10.7554/eLife.79179.
2
Diabetes tolerogenic vaccines targeting antigen-specific inflammation.针对抗原特异性炎症的糖尿病耐受性疫苗。
Hum Vaccin Immunother. 2015;11(2):522-30. doi: 10.1080/21645515.2014.1004024.
3
Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A.
Eur J Pediatr. 2004 Sep;163(9):561-2. doi: 10.1007/s00431-004-1497-7. Epub 2004 Jul 8.
4
Tacrolimus in refractory polymyositis with interstitial lung disease.他克莫司用于治疗伴有间质性肺病的难治性多发性肌炎。
Lancet. 1999 May 22;353(9166):1762-3. doi: 10.1016/S0140-6736(99)01927-3.
5
The use of therapeutic drug monitoring to optimise immunosuppressive therapy.使用治疗药物监测来优化免疫抑制治疗。
Clin Pharmacokinet. 1996 Feb;30(2):107-40. doi: 10.2165/00003088-199630020-00003.
6
New immunosuppressive drugs: mechanistic insights and potential therapeutic advances.新型免疫抑制药物：作用机制洞察与潜在治疗进展
Immunol Rev. 1993 Dec;136:71-98. doi: 10.1111/j.1600-065x.1993.tb00655.x.
7
Therapeutic advances in immunosuppression.免疫抑制治疗的进展
Clin Exp Immunol. 1994 Dec;98(3):351-7. doi: 10.1111/j.1365-2249.1994.tb05496.x.
8
Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes.自身免疫性肝病中循环细胞间黏附分子-1（ICAM-1）以及细胞因子刺激的人肝细胞产生ICAM-1的证据。
Clin Exp Immunol. 1994 Jan;95(1):83-90. doi: 10.1111/j.1365-2249.1994.tb06019.x.
9
Autoimmune hepatitis. Evolving concepts and treatment strategies.自身免疫性肝炎。不断演变的概念和治疗策略。
Dig Dis Sci. 1995 Feb;40(2):435-56. doi: 10.1007/BF02065434.
10
Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial.19例参与开放标签药物安全性试验的慢性进行性多发性硬化症患者中，FK 506（他克莫司）对表达CD25和CD45RA抗原的循环CD4 + T细胞的影响。
Autoimmunity. 1994;19(2):89-98. doi: 10.3109/08916939409009536.
本文引用的文献
1
Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production.FK506对自身免疫性甲状腺疾病的抑制作用：对甲状腺浸润细胞、黏附分子表达及抗甲状腺球蛋白抗体产生的影响。
Clin Exp Immunol. 1993 Mar;91(3):368-75. doi: 10.1111/j.1365-2249.1993.tb05911.x.
2
Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome.FK506治疗激素抵抗型肾病综合征的初步试验
Nephrol Dial Transplant. 1993;8(11):1286-90.
3
4
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.辅助性T细胞1型和辅助性T细胞2型：不同的淋巴因子分泌模式导致不同的功能特性。
Annu Rev Immunol. 1989;7:145-73. doi: 10.1146/annurev.iy.07.040189.001045.
5
FK 506 for liver, kidney, and pancreas transplantation.用于肝脏、肾脏和胰腺移植的FK 506。
Lancet. 1989 Oct 28;2(8670):1000-4. doi: 10.1016/s0140-6736(89)91014-3.
6
FK-506--how much potential?FK-506——潜力有多大？
Immunol Today. 1989 Jan;10(1):6-9. doi: 10.1016/0167-5699(89)90057-1.
7
The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes.免疫抑制剂FK506可选择性抑制早期T细胞活化基因的表达。
J Immunol. 1989 Jul 15;143(2):718-26.
8
Effects of FK-506 on collagen arthritis in mice.FK-506对小鼠胶原性关节炎的影响。
Transplant Proc. 1989 Feb;21(1 Pt 1):1053-5.
9
Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus.新型免疫抑制药物FK-506对小鼠系统性红斑狼疮的作用
Clin Immunol Immunopathol. 1989 Apr;51(1):110-7. doi: 10.1016/0090-1229(89)90211-0.
10
Immunosuppressive effect of FK506 on experimental allergic encephalomyelitis in rats.FK506对大鼠实验性变态反应性脑脊髓炎的免疫抑制作用。
Int J Immunopharmacol. 1988;10(8):991-5. doi: 10.1016/0192-0561(88)90046-x.
Zotero 插件